Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efprezimod alfa for aGVHD prevention in HCT
NCT04095858Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Efprezimod alfa + SOC with Placebo + SOC (2 arms). Primary endpoint: Grade III-IV Acute Graft-Versus-Host Disease-Free Survival at 180 days. Started Jan 2021; status: terminated.
02
Drugs
efprezimod alfa
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04095858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095858.